Research programme: age-related macular degeneration therapy - Medigene AG
Alternative Names: EndoGreenLatest Information Update: 30 Aug 2010
At a glance
- Originator MediGene AG
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Age-related macular degeneration
Most Recent Events
- 15 Mar 2007 EndoGreen is available for licensing worldwide (http://www.medigene.com)
- 15 Mar 2007 Preclinical trials in Age-related macular degeneration in Germany (unspecified route)